1. Home
  2. NGNE vs PGC Comparison

NGNE vs PGC Comparison

Compare NGNE & PGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$34.41

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Logo Peapack-Gladstone Financial Corporation

PGC

Peapack-Gladstone Financial Corporation

HOLD

Current Price

$46.54

Market Cap

836.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
PGC
Founded
2003
1921
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
836.7M
IPO Year
2014
1997

Fundamental Metrics

Financial Performance
Metric
NGNE
PGC
Price
$34.41
$46.54
Analyst Decision
Strong Buy
Buy
Analyst Count
7
2
Target Price
$63.57
$40.50
AVG Volume (30 Days)
310.4K
220.8K
Earning Date
05-08-2026
04-22-2026
Dividend Yield
N/A
0.48%
EPS Growth
0.93
13.51
EPS
N/A
0.80
Revenue
N/A
$282,995,000.00
Revenue This Year
N/A
$32.39
Revenue Next Year
N/A
$12.64
P/E Ratio
N/A
$57.10
Revenue Growth
N/A
24.05
52 Week Low
$15.93
$24.45
52 Week High
$43.66
$49.14

Technical Indicators

Market Signals
Indicator
NGNE
PGC
Relative Strength Index (RSI) 47.61 53.61
Support Level $18.24 $44.79
Resistance Level $37.27 $47.18
Average True Range (ATR) 3.04 1.48
MACD -0.65 -0.19
Stochastic Oscillator 17.67 63.90

Price Performance

Historical Comparison
NGNE
PGC

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About PGC Peapack-Gladstone Financial Corporation

Peapack Gladstone Financial Corp is a bank holding company. Through its subsidiaries, the company offers various wealth management, investment banking, and commercial and personal banking solutions to its clients. The company has two reportable segments: Banking, which generates the maximum revenue, and Wealth Management. The Banking segment includes commercial, commercial real estate, multifamily, residential, and consumer lending activities; treasury management services; escrow management; deposit generation; operation of ATMs; telephone and internet banking services; credit card services, etc. The Wealth Management segment offers investment management services for individuals and institutions; personal trust services; and other financial planning and advisory services.

Share on Social Networks: